Federal Circuit Upholds Invalidation of Merck's Multiple Sclerosis Drug Patent
Key Insights
The Federal Circuit (search) upheld a Patent Trial and Appeal Board (search) decision invalidating a Merck KGaA unit's patent for a multiple sclerosis (search) drug.
Senior Judge Richard Linn issued a precedential opinion clarifying interpretation of "by others" and "by another" phrases in pre-2011 Patent Act obviousness determinations.
Hopewell Pharma Ventures Inc. (search) successfully challenged the patent technology as obvious in January 2023 proceedings.
The Federal Circuit (search) has upheld a Patent Trial and Appeal Board (search) decision invalidating a Merck KGaA unit's patent covering a multiple sclerosis (search) drug, delivering a precedential ruling that clarifies critical language in patent obviousness determinations.
Court Clarifies Patent Act Interpretation
Senior Judge Richard Linn authored the precedential opinion, which specifically addressed how courts should interpret the phrases "by others" and "by another" in Patent Act provisions that define what evidence can be used to prove patent obviousness. The clarification applies to patents filed before the 2011 America Invents Act.
The ruling reinforces the Federal Circuit (search)'s precedential interpretation of key language in the Patent Act, providing important guidance for future patent validity challenges in the pharmaceutical sector.
Patent Challenge Background
Hopewell Pharma Ventures Inc. (search) initiated the patent challenge at the Patent Trial and Appeal Board (search) in January 2023, arguing that the multiple sclerosis (search) drug technology was obvious. The challenge came after Merck sued Hopewell in Delaware seeking to enforce its patent rights.
The Patent Trial and Appeal Board (search) sided with Hopewell's obviousness argument, finding the patent invalid. Merck's subsequent appeal to the Federal Circuit (search) was unsuccessful, with the appellate court upholding the tribunal's decision.
Implications for Pharmaceutical Patents
The Federal Circuit (search)'s precedential ruling provides clarity on a fundamental aspect of patent law that affects how obviousness challenges are evaluated. The decision specifically impacts patents filed under the pre-2011 version of the Patent Act, potentially affecting numerous existing pharmaceutical patents that fall under this timeframe.
The invalidation of Merck's multiple sclerosis (search) patent demonstrates the ongoing challenges pharmaceutical companies face in maintaining patent protection for their drug technologies, particularly when facing obviousness challenges based on prior art and existing knowledge in the field.